Csk-话题@MedSci

#Csk#

97篇内容 | 1229人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1777227, encodeId=1b871e772273e, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=JCEM：何种PCSK9基因突变类型能降低LDL-C水平？, objectType=article, longId=43081, objectId=854b43081da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=854b43081da, replyNumber=0, likeNumber=30, createdTime=2015-07-26, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=854b43081da, moduleTitle=JCEM：何种PCSK9基因突变类型能降低LDL-C水平？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=854b43081da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777229, encodeId=483d1e7722955, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=PCSK9抑制剂竞争白热化各大医药巨头抢占市场, objectType=article, longId=43795, objectId=a88243e95ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a88243e95ba, replyNumber=0, likeNumber=25, createdTime=2015-03-15, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a88243e95ba, moduleTitle=PCSK9抑制剂竞争白热化各大医药巨头抢占市场, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a88243e95ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777234, encodeId=9d901e7723456, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=新一代降脂单抗药PCSK9呼之欲出, objectType=article, longId=52297, objectId=a02d5229e21, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a02d5229e21, replyNumber=0, likeNumber=36, createdTime=2015-08-19, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a02d5229e21, moduleTitle=新一代降脂单抗药PCSK9呼之欲出, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a02d5229e21)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777232, encodeId=5c6a1e77232fe, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=NEJM：PCSK9抑制剂Evolocumab可显著降低LDL-C水平和心血管事件（OSLER研究）, objectType=article, longId=49563, objectId=032749563aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=032749563aa, replyNumber=0, likeNumber=40, createdTime=2016-01-24, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=032749563aa, moduleTitle=NEJM：PCSK9抑制剂Evolocumab可显著降低LDL-C水平和心血管事件（OSLER研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=032749563aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777230, encodeId=23851e77230aa, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=PCSK9抗体药物在手！辉瑞酝酿开发PCSK9小分子阻断剂药物, objectType=article, longId=45584, objectId=a925455845d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a925455845d, replyNumber=0, likeNumber=31, createdTime=2015-07-03, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a925455845d, moduleTitle=PCSK9抗体药物在手！辉瑞酝酿开发PCSK9小分子阻断剂药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a925455845d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777226, encodeId=6c151e77226ab, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=赛诺菲、Regeneron开发PCSK9新药alirocumab临床试验击败Zetia, objectType=article, longId=42968, objectId=df2042968c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2042968c5, replyNumber=0, likeNumber=34, createdTime=2014-11-24, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2042968c5, moduleTitle=赛诺菲、Regeneron开发PCSK9新药alirocumab临床试验击败Zetia, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2042968c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777225, encodeId=85311e7722594, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Lancet：PCSK9单抗evolocumab能显著降低家族性高胆固醇血症患者LDL水平 (TESLA研究和RUTHERFORD-2研究）, objectType=article, longId=40894, objectId=400c4089478, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=400c4089478, replyNumber=0, likeNumber=44, createdTime=2014-11-29, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=400c4089478, moduleTitle=Lancet：PCSK9单抗evolocumab能显著降低家族性高胆固醇血症患者LDL水平 (TESLA研究和RUTHERFORD-2研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=400c4089478)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777224, encodeId=8c941e7722464, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=ESC 2014 ：国内外专家点评PCSK9抑制剂远期效果仍待验证, objectType=article, longId=39904, objectId=46043990410, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46043990410, replyNumber=0, likeNumber=38, createdTime=2015-01-01, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46043990410, moduleTitle=ESC 2014 ：国内外专家点评PCSK9抑制剂远期效果仍待验证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46043990410)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777223, encodeId=4e901e77223f7, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=赛诺菲PCSK9抑制剂alirocumab 9个III期均达主要疗效终点, objectType=article, longId=38618, objectId=b1903861805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1903861805, replyNumber=0, likeNumber=31, createdTime=2014-11-03, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1903861805, moduleTitle=赛诺菲PCSK9抑制剂alirocumab 9个III期均达主要疗效终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1903861805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777222, encodeId=8e331e77222d3, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=郭艺芳：PCSK9单克隆抗体能否撼动他汀霸主地位？, objectType=article, longId=32846, objectId=95f2328469f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95f2328469f, replyNumber=0, likeNumber=30, createdTime=2014-12-17, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95f2328469f, moduleTitle=郭艺芳：PCSK9单克隆抗体能否撼动他汀霸主地位？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95f2328469f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777218, encodeId=98eb1e7721801, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=FDA要求赛诺菲评估alirocumab认知风险 PCSK9抑制剂研发难度可能加大, objectType=article, longId=31688, objectId=117b31688b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=117b31688b0, replyNumber=0, likeNumber=24, createdTime=2014-07-26, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=117b31688b0, moduleTitle=FDA要求赛诺菲评估alirocumab认知风险 PCSK9抑制剂研发难度可能加大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=117b31688b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777221, encodeId=eab71e7722166, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=刘梅林：PCSK9单克隆抗体“不负众望”, objectType=article, longId=32767, objectId=75e332e67bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75e332e67bb, replyNumber=0, likeNumber=35, createdTime=2014-07-16, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75e332e67bb, moduleTitle=刘梅林：PCSK9单克隆抗体“不负众望”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75e332e67bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777220, encodeId=27f61e77220a2, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=ACC 2014：PCSK9抑制剂显著降低低密度脂蛋白水平, objectType=article, longId=32745, objectId=a8ae32e4548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8ae32e4548, replyNumber=0, likeNumber=37, createdTime=2014-05-09, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8ae32e4548, moduleTitle=ACC 2014：PCSK9抑制剂显著降低低密度脂蛋白水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8ae32e4548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777219, encodeId=672c1e7721917, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=安进PCSK9抑制剂evolocumab III期TESLA达主要终点, objectType=article, longId=32022, objectId=e7cc32022c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7cc32022c7, replyNumber=0, likeNumber=33, createdTime=2014-05-24, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7cc32022c7, moduleTitle=安进PCSK9抑制剂evolocumab III期TESLA达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7cc32022c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777217, encodeId=46081e77217cb, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Nat. Rev. Endocrinol.: PCSK9或为降低LDL胆固醇新靶点, objectType=article, longId=19287, objectId=2b701928efc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b701928efc, replyNumber=0, likeNumber=29, createdTime=2013-12-20, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b701928efc, moduleTitle=Nat. Rev. Endocrinol.: PCSK9或为降低LDL胆固醇新靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b701928efc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777216, encodeId=2f691e7721672, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=LANCET：PCSK单克隆抗体降低家族性高胆固醇血症患者的低密度脂蛋白胆固醇试验, objectType=article, longId=12338, objectId=b7df12338a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7df12338a9, replyNumber=0, likeNumber=36, createdTime=2013-01-04, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7df12338a9, moduleTitle=LANCET：PCSK单克隆抗体降低家族性高胆固醇血症患者的低密度脂蛋白胆固醇试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7df12338a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777215, encodeId=ffa51e7721573, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Nat. Cell Biol.：揭示蛋白LYP与CSK脱离如何干扰免疫系统, objectType=article, longId=5259, objectId=0d445259ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d445259ba, replyNumber=0, likeNumber=34, createdTime=2012-05-27, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d445259ba, moduleTitle=Nat. Cell Biol.：揭示蛋白LYP与CSK脱离如何干扰免疫系统, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d445259ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Csk

2020-05-29

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

JCEM：何种PCSK9基因突变类型能降低LDL-C水平？

2015-07-26

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

PCSK9抑制剂竞争白热化各大医药巨头抢占市场

2015-03-15

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

新一代降脂单抗药PCSK9呼之欲出

2015-08-19

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

NEJM：PCSK9抑制剂Evolocumab可显著降低LDL-C水平和心血管事件（OSLER研究）

2016-01-24

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

PCSK9抗体药物在手！辉瑞酝酿开发PCSK9小分子阻断剂药物

2015-07-03

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

赛诺菲、Regeneron开发PCSK9新药alirocumab临床试验击败Zetia

2014-11-24

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Lancet：PCSK9单抗evolocumab能显著降低家族性高胆固醇血症患者LDL水平 (TESLA研究和RUTHERFORD-2研究）

2014-11-29

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

ESC 2014 ：国内外专家点评PCSK9抑制剂远期效果仍待验证

2015-01-01

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

赛诺菲PCSK9抑制剂alirocumab 9个III期均达主要疗效终点

2014-11-03

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

郭艺芳：PCSK9单克隆抗体能否撼动他汀霸主地位？

2014-12-17

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

FDA要求赛诺菲评估alirocumab认知风险 PCSK9抑制剂研发难度可能加大

2014-07-26

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

刘梅林：PCSK9单克隆抗体“不负众望”

2014-07-16

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

ACC 2014：PCSK9抑制剂显著降低低密度脂蛋白水平

2014-05-09

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

安进PCSK9抑制剂evolocumab III期TESLA达主要终点

2014-05-24

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Nat. Rev. Endocrinol.: PCSK9或为降低LDL胆固醇新靶点

2013-12-20

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

LANCET：PCSK单克隆抗体降低家族性高胆固醇血症患者的低密度脂蛋白胆固醇试验

2013-01-04

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Nat. Cell Biol.：揭示蛋白LYP与CSK脱离如何干扰免疫系统

2012-05-27

科室
- - 订阅+
  - 更多科室
工具
服务